Serplulimab and Bevacizumab injection

DRUG2 trials

Sponsors

Fujian Cancer Hospital, Shanghai General Hospital, China

Conditions

Lung AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaPD-1 InhibitorStage IV Non-small Cell Lung CancerVEGF

Phase 2

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Fujian Cancer HospitalLung Adenocarcinoma, PD-1 Inhibitor, Stage IV Non-small Cell Lung Cancer +1

Start: 2023-01-10End: 2024-01-10Target: 50Updated: 2023-01-09

Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Not yet recruitingNCT07733050

Shanghai General Hospital, ChinaMetastatic Pancreatic Ductal Adenocarcinoma

Start: 2026-08-01End: 2028-08-01Target: 34Updated: 2026-07-29